Compare IONQ & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONQ | JAZZ |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 16.1B |
| IPO Year | 2020 | 2007 |
| Metric | IONQ | JAZZ |
|---|---|---|
| Price | $31.02 | $205.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 22 |
| Target Price | $64.06 | ★ $294.27 |
| AVG Volume (30 Days) | ★ 17.5M | 715.4K |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | $1,235,000,000.00 | ★ $1,618,693,000.00 |
| Revenue This Year | $250.04 | $10.68 |
| Revenue Next Year | $77.55 | $5.72 |
| P/E Ratio | ★ N/A | $29.76 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $128.80 |
| 52 Week High | $73.65 | $266.38 |
| Indicator | IONQ | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 30.26 |
| Support Level | $30.50 | $194.77 |
| Resistance Level | $34.18 | $207.48 |
| Average True Range (ATR) | 2.10 | 7.31 |
| MACD | -0.60 | -0.23 |
| Stochastic Oscillator | 9.49 | 0.94 |
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.